Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Boyko

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 18, 2024
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohortGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Neurodegenerative Disease Management|August 3, 2023
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2026
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trialAaron Miller, Jeffrey A Cohen, Arnon Karni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Frontiers in Immunology|February 4, 2020
Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic PeptidesAzad Mamedov, Nadezhda Vorobyeva, Ioanna Filimonova, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2010
The management of multiple sclerosis in children: a European viewAngelo Ghezzi, Brenda Banwell, Alexey Boyko, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 18, 2024
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohortGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Neurodegenerative Disease Management|August 3, 2023
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2026
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trialAaron Miller, Jeffrey A Cohen, Arnon Karni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Frontiers in Immunology|February 4, 2020
Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic PeptidesAzad Mamedov, Nadezhda Vorobyeva, Ioanna Filimonova, et al.
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2010
The management of multiple sclerosis in children: a European viewAngelo Ghezzi, Brenda Banwell, Alexey Boyko, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Pageof 7